Comparative Pharmacology
Head-to-head clinical analysis: LOMOTIL versus VIBERZI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOMOTIL versus VIBERZI.
LOMOTIL vs VIBERZI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenoxylate is a meperidine congener that acts as an opioid receptor agonist, inhibiting gastrointestinal motility and prolonging transit time; atropine is added to discourage abuse at high doses.
Guanylate cyclase-C agonist; increases intracellular cyclic guanosine monophosphate (cGMP) leading to activation of cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid secretion and accelerated transit.
Adults: 2 tablets (2.5 mg diphenoxylate/0.025 mg atropine) orally four times daily until control of diarrhea is achieved; maintenance dose is 2 tablets once or twice daily. Maximum dose: 8 tablets (20 mg diphenoxylate) per day.
100 mg orally three times daily with meals.
None Documented
None Documented
Diphenoxylate: 2.5-3.5 hours; Difenoxin (active metabolite): 12-24 hours. Clinically, antidiarrheal effect is prolonged due to metabolite accumulation.
Terminal elimination half-life is approximately 8-9 hours, supporting twice-daily dosing.
Primarily renal (50-70% as metabolites, <5% unchanged) and fecal (30-50% via biliary excretion).
Primarily fecal (approximately 95% of absorbed dose) with minimal renal excretion (<1%).
Category C
Category C
Antidiarrheal
Antidiarrheal